WO2009131752A3 - Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration - Google Patents

Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration Download PDF

Info

Publication number
WO2009131752A3
WO2009131752A3 PCT/US2009/036117 US2009036117W WO2009131752A3 WO 2009131752 A3 WO2009131752 A3 WO 2009131752A3 US 2009036117 W US2009036117 W US 2009036117W WO 2009131752 A3 WO2009131752 A3 WO 2009131752A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue regeneration
construct
therapeutic
release
biological
Prior art date
Application number
PCT/US2009/036117
Other languages
French (fr)
Other versions
WO2009131752A2 (en
Inventor
Jay N. Schapira
Raj Makkar
Original Assignee
Schapira Jay N
Raj Makkar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/150,329 external-priority patent/US20080311172A1/en
Application filed by Schapira Jay N, Raj Makkar filed Critical Schapira Jay N
Priority to EP09734987A priority Critical patent/EP2282718A2/en
Priority to CN2009801240870A priority patent/CN102083412A/en
Publication of WO2009131752A2 publication Critical patent/WO2009131752A2/en
Publication of WO2009131752A3 publication Critical patent/WO2009131752A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • A61L2300/61—Coatings having two or more layers containing two or more active agents in different layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces

Abstract

A biologically engineered construct comprising of a polymeric biomatrix (100), designed with a nanophase texture (106), and a therapeutic agent (104 or 300) for the purpose of tissue regeneration and/or controlled delivery of regenerative factors and therapeutic substances after it is implanted into tissues, vessels, or luminal structures within the body. The therapeutic agent (104 or 300) may be a therapeutic substance (104) or a biological agent (300), such as antibodies, ligands, or living cells. The nanophase construct is designed to maximize lumen size, promote tissue remodeling, and ultimately make the implant more biologically compatible. The nano-textured polymeric biomatrix (100) may comprise one or more layers containing therapeutic substances (104) and/or beneficial biological agents (300) for the purpose of controlled, physiological, differential substance/drug delivery into the luminal and abluminal surfaces of the vessel or lumen, and the attraction of target molecules/cells that will regenerate functional tissue. The topographic and biocompatible features of this layered biological construct provides an optimal environment for tissue regeneration along with a pro grammed -release, drug delivery system to improve physiological tolerance of the implant, and to maximize the cellular survival, migration, and integration within the implanted tissues.
PCT/US2009/036117 2008-04-25 2009-03-05 Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration WO2009131752A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09734987A EP2282718A2 (en) 2008-04-25 2009-03-05 Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
CN2009801240870A CN102083412A (en) 2008-04-25 2009-03-05 Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/150,329 2008-04-25
US12/150,329 US20080311172A1 (en) 2007-04-25 2008-04-25 Programmed-release, nanostructured biological construct
US22113908A 2008-07-31 2008-07-31
US12/221,139 2008-07-31

Publications (2)

Publication Number Publication Date
WO2009131752A2 WO2009131752A2 (en) 2009-10-29
WO2009131752A3 true WO2009131752A3 (en) 2009-12-17

Family

ID=41217351

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/036117 WO2009131752A2 (en) 2008-04-25 2009-03-05 Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration

Country Status (3)

Country Link
EP (1) EP2282718A2 (en)
CN (1) CN102083412A (en)
WO (1) WO2009131752A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5569398B2 (en) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス Device for promoting hemostasis and / or wound healing
CN102905732A (en) * 2010-03-15 2013-01-30 弗罗桑医疗设备公司 A method for promotion of hemostasis and/or wound healing
CN101927033B (en) * 2010-08-09 2013-06-12 华南理工大学 PHBV (Poly (HydroxyButyrate-hydroxyValerate)) nano fiber support material as well as preparation method and application thereof
WO2012173555A1 (en) 2011-06-13 2012-12-20 Dentsply Ih Ab Collagen coated article
EP2731555B1 (en) * 2011-07-13 2018-11-07 Vivex Biomedical, Inc. Spinal implants with stem cells
CA2841336A1 (en) * 2011-07-13 2012-01-19 Cadorel, Catherine Composite part for endosseous implantation, and method for manufacturing such a part
EP2822474B1 (en) 2012-03-06 2018-05-02 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
AU2013275758B2 (en) 2012-06-12 2015-03-12 Ferrosan Medical Devices A/S Dry haemostatic composition
CN103055302B (en) * 2013-01-08 2014-05-14 福建医科大学附属协和医院 Ultrasonic biological effect mediated recombinant human endostatin controlled release preparation
AU2014283170B2 (en) 2013-06-21 2017-11-02 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
CN103598927A (en) * 2013-10-17 2014-02-26 上海交通大学 Degradable magnesium alloy nerve conduit for nerve defect repair and preparation method of nerve conduit
CN103656750B (en) * 2013-12-07 2014-12-24 西南交通大学 Method for improving various bionic functions on surface of cardiovascular implant material
JP6489485B2 (en) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス Dry composition containing an extrusion enhancing factor
CN103893826A (en) * 2014-03-03 2014-07-02 重庆大学 Titanium alloy surface modification method for regulating and controlling stem cell differentiation and promoting in-vivo bone formation
BR112017007466B1 (en) 2014-10-13 2021-03-02 Ferrosan Medical Devices A/S method for preparing a dry composition, method for reconstituting the dry composition, paste, dry composition, container, homeostatic kit, and, using a dry composition
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN104707180B (en) * 2015-02-06 2017-01-25 福州大学 BMP loaded silk fibroin/collagen scaffold material and preparation method thereof
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN109735434B (en) * 2016-09-14 2022-09-23 四川蓝光英诺生物科技股份有限公司 Artificial tissue precursors and methods of making the same
AU2017317607B2 (en) * 2016-10-19 2018-05-17 Beta Cell Technologies Pty Ltd Cell population seeding in dermal matrices for endocrine
US20200385666A1 (en) * 2018-01-24 2020-12-10 Yokogawa Electric Corporation Cell culture carrier and cell culture container
US20210369918A1 (en) * 2018-04-25 2021-12-02 Sapporo Medical University Cell sheet for transplantation into living body and method for producing same
AU2019266529A1 (en) 2018-05-09 2020-12-03 Ethicon Inc. Method for preparing a haemostatic composition
CN110755608A (en) * 2018-07-27 2020-02-07 上海微创医疗器械（集团）有限公司 Application of specific antibody, implanted medical instrument and preparation method thereof
US20210353831A1 (en) * 2018-10-03 2021-11-18 Establishment Labs S.A. Scaffolding for implantable medical devices and methods of use thereof
CN109172037B (en) * 2018-10-22 2023-09-12 上海交通大学医学院附属上海儿童医学中心 Design and application of multi-layer tissue engineering tracheal stent based on 3D printing and electrostatic spinning technology
AU2018453854B2 (en) * 2018-12-20 2023-03-16 Bio-Recell Ltd. Membrane for separation of stem cells from biological samples, production process of said membrane, and process and device for separation, comprising said membrane
CN109938875A (en) * 2019-03-07 2019-06-28 宁波光远致信生物科技有限公司 A kind of nerve prosthesis and its preparation method and application
MX2021011780A (en) * 2019-03-29 2021-11-12 Tdbt Ip Inc Tissue and organ replacements and methods of making thereof.
EP4100071A1 (en) 2020-02-07 2022-12-14 King's College London Tissue regeneration patch

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018647A2 (en) * 2005-05-02 2007-02-15 Emory University Multifunctional nanostructures, methods of synthesizing thereof, and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018647A2 (en) * 2005-05-02 2007-02-15 Emory University Multifunctional nanostructures, methods of synthesizing thereof, and methods of use thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLINDT ET AL.: "A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelialprogenitor cells.", JOUR AM COLL CARDIOL, vol. 47, no. 9, 2 May 2006 (2006-05-02), pages 1786 - 1795, XP028006955 *
FINKELSTEIN ET AL.: "Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics.", CIRCULATION, vol. 107, no. 5, 11 February 2003 (2003-02-11), pages 777 - 84, XP003009054 *
HUANG ET AL.: "Hemocompatibility of layer-by-layer hyaluronic acid/heparin nanostructure coating on stainless steel for cardiovascular stents and its use for drug delivery", J NANOSCI NANOTECHNOL., vol. 6, no. 9-10, September 2006 (2006-09-01), pages 3163 - 3170, XP008134090 *
JIN ET AL.: "Nanofibrous Scaffolds Incorporating PDGF-BB Microspheres Induce Chemokine Expression and Tissue Neogenesis In Vivo.", PLOS ONE, vol. 3, no. 3, 5 March 2008 (2008-03-05), pages E1729 1 - 9, XP002609816 *
LI ET AL.: "Multilineage differentiation of human mesenchymal stem cells in a three-dimensional nanofibrous scaffold.", BIOMATERIALS, vol. 26, no. 25, September 2005 (2005-09-01), pages 5158 - 66, XP027768238 *
NA ET AL.: "Self-assembled hydrogel nanoparticles responsive to tumor extracellular pH from pullulan derivative/sulfonamide conjugate: characterization, aggregation, and adriamycin release in vitro", PHARM RES, vol. 19, no. 5, May 2002 (2002-05-01), pages 681 - 688, XP009031095 *
ONG ET AL.: "How to accelerate the endothelialization of stents.", ARCH MAL COEUR VAISS, vol. 98, no. 2, February 2005 (2005-02-01), pages 123 - 126, XP008146311 *
SAHOO ET AL.: "Development of hybrid polymer scaffolds for potential applications in ligament and tendon tissue engineering.", BIOMED MATERIALS, vol. 2, no. 3, September 2007 (2007-09-01), pages 169 - 73, XP020125624 *
SWANSON ET AL.: "Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia.", JOUR. INVASIVE CARDIOL, vol. 15, no. 12, December 2003 (2003-12-01), pages 688 - 692, XP008094065 *
ZHANG ET AL.: "Biomimetic and bioactive nanofibrous scaffolds from electrospun composite nanofibers.", INT J NANOMEDICINE, vol. 2, no. 4, December 2007 (2007-12-01), pages 623 - 638, XP008146304 *

Also Published As

Publication number Publication date
WO2009131752A2 (en) 2009-10-29
EP2282718A2 (en) 2011-02-16
CN102083412A (en) 2011-06-01

Similar Documents

Publication Publication Date Title
WO2009131752A3 (en) Programmed-release, nanostructured biological construct for stimulating cellular engraftment for tissue regeneration
US11730860B2 (en) Methods and devices for cellular transplantation
Smith et al. Harnessing macrophage plasticity for tissue regeneration
US10751280B2 (en) Implantable cellular and biotherapeutic agent delivery canister
JP4959130B2 (en) Apparatus and method for minimally invasive implantation of biomaterials
US20080311172A1 (en) Programmed-release, nanostructured biological construct
JP2015165892A (en) Extracellular matrix encasement structures and methods
Reichert et al. 2010 Panel on the biomaterials grand challenges
WO2007059253A3 (en) Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2007030512A3 (en) Graft implant containing drug crystals
Zahid et al. Leveraging the advancements in functional biomaterials and scaffold fabrication technologies for chronic wound healing applications
Coindre et al. Methacrylic acid copolymer coating of polypropylene mesh chamber improves subcutaneous islet engraftment
Hossain et al. The importance of advance biomaterials in modern technology: a review
Grundfest‐Broniatowski What would surgeons like from materials scientists?
KR101554696B1 (en) Mobile bio-scaffold controlled by magnetic field and manufacturing method thereof
US11857670B2 (en) Implantable cellular and biotherapeutic agent delivery canister
US20220142916A1 (en) Implantable cellular and biotherapeutic agent delivery canister
US20230059851A1 (en) Implantable cellular and biotherapeutic agent delivery canister
EP3190969B1 (en) Method for the manufacturing of coated implants
Peramo Novel Double Lumen Catheter for Drug Delivery at the Skin-Catheter Interface
US20240024089A1 (en) Methods and devices for providing oxygen to encapsulated cells
Contreras-García et al. Biomedical Devices Based on Smart Polymers
Ding et al. Advanced construction strategies to obtain nanocomposite hydrogels for bone repair and regeneration
WO2023016677A1 (en) Open type implantable cell delivery device
Khademhosseini HEAL project aims to regenerate human limbs by 2030

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124087.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734987

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009734987

Country of ref document: EP